Trial · NCT02871778
Participant flow96
How many started, completed or left each group, period by period.
1 to 20 of 96
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A: Treatment Period 1 | STARTED | Part A: VX-371 in Hypertonic Saline (HS), Then HS | 43 | |
| Part A: Treatment Period 1 | STARTED | Part A: HS, Then VX-371 in HS | 41 | |
| Part A: Treatment Period 1 | STARTED | Part A: VX-371, Then Placebo | 21 | |
| Part A: Treatment Period 1 | STARTED | Part A: Placebo, Then VX-371 | 18 | |
| Part A: Treatment Period 1 | STARTED | Part B: VX-371 in HS + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | STARTED | Part B: HS + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | STARTED | Part B: VX-371 + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | STARTED | Part B: Placebo + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part A: VX-371 in Hypertonic Saline (HS), Then HS | 44 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part A: HS, Then VX-371 in HS | 40 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part A: VX-371, Then Placebo | 21 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part A: Placebo, Then VX-371 | 18 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part B: VX-371 in HS + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part B: HS + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part B: VX-371 + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | Safety Analysis Set | Part B: Placebo + Ivacaftor | 0 | |
| Part A: Treatment Period 1 | COMPLETED | Part A: VX-371 in Hypertonic Saline (HS), Then HS | 40 | |
| Part A: Treatment Period 1 | COMPLETED | Part A: HS, Then VX-371 in HS | 37 | |
| Part A: Treatment Period 1 | COMPLETED | Part A: VX-371, Then Placebo | 18 | |
| Part A: Treatment Period 1 | COMPLETED | Part A: Placebo, Then VX-371 | 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02871778/flow